Overview

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Erlotinib Hydrochloride
Mitogens